Open access · OA
via Europe PMC
Triterpenoids - future multi-target compounds against obesity and towards restoration of metabolic health.
Becker J, Ebert BE, Festel G, Blank LM.
Frontiers in aging · 2026
Telomere attrition
Deregulated nutrient-sensing
Altered intercellular communication
Disabled macroautophagy
Microbiome / FMT
Human
Review
Abstract
Obesity and its associated diseases represent one of the most urgent public health crises of our time, affecting billions worldwide. Current pharmacological agents, such as GLP-1 and GLP-1/GIP receptor agonists, have demonstrated high clinical efficacy in diabetes and weight management. However, the required lifelong medication is often limited by high economic costs and severe side effects, including gastrointestinal complications. Consequently, the search for complementary therapies is invaluable. This review highlights the potential of natural triterpenoids in obesity management by shifting the focus towards long-term metabolic restoration. Triterpenoids can serve as multi-target agents that address key pathways, such as AMPK and Akt/mTOR(definition), thereby positively regulating autophagy(definition) processes and improving metabolic imbalances. Celastrol, for example, acts as a leptin sensitizer, restoring satiety signaling; ursolic acid drives body recomposition by enhancing energy expenditure; and ginsenosides modulate multiple processes, including browning, adipogenesis, lipogenesis, and satiety signaling. Furthermore, oleanolic acid promotes pathways associated with cellular healthspan(definition) by activating telomerase, while betulinic acid suppresses <i>de novo</i> fatty acid synthesis independently of food intake. However, low oral bioavailability remains the major challenge to successfully translating these findings from animal models to clinical applications. Advanced strategies, such as sustainable bioproduction via genetically modified microorganisms, engineered probiotics, or nanotechnology-based delivery systems, offer promising opportunities to overcome these pharmacokinetic and safety limitations. Addressing these barriers is essential to translate triterpenoids into therapeutic agents for human metabolic health and healthy aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fragi.2026.1939566
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
J, B., BE, E., G, F., & LM., B. (2026). Triterpenoids - future multi-target compounds against obesity and towards restoration of metabolic health. <em>Frontiers in aging</em>. https://doi.org/10.3389/fragi.2026.1939566
Vancouver
J B, BE E, G F, LM. B. Triterpenoids - future multi-target compounds against obesity and towards restoration of metabolic health. Frontiers in aging. 2026. doi:10.3389/fragi.2026.1939566.
BibTeX
@article{becker2026Triter,
title = {Triterpenoids - future multi-target compounds against obesity and towards restoration of metabolic health.},
author = {Becker J and Ebert BE and Festel G and Blank LM.},
journal = {Frontiers in aging},
year = {2026},
doi = {10.3389/fragi.2026.1939566},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Biomedicine 2026
Open access · CC-BY
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging
Molecular biomedicine 2026
Open access · OA
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging.
Die Pharmazie 2025
Open access · CC-BY
Metformin and the molecular pathways of aging: Searching for the modern elixir of life
American Journal of Cancer Research 2026
Preprint · OA
Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond
International journal of molecular sciences 2025
Open access · OA
Apiin Promotes Healthy Aging in <i>C. elegans</i> Through Nutritional Activation of DAF-16/FOXO, Enhancing Fatty Acid Catabolism and Oxidative Stress Resistance.
Aging Pathobiology and Therapeutics 2026
Open access · CC-BY